 SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 PRNewswire -- Rigel Pharmaceuticals, Inc. Nasdaq: RIGL, today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases , an official publication of the Infectious Disease Society of America. 